New clinical trial aims to optimize pain management and reduce opioid use after mastectomy
MSN highlights Cancer Center research
MSN highlighted a new University of Cincinnati Cancer Center clinical trial aimed to optimize pain management and reduce the need for opioids after mastectomy procedures.
Alicia Heelan, MD, and Bradley Budde, MD, are leading the trial, funded by a $50,000 pilot grant supported by contributions from Ride Cincinnati through the Cancer Center Pilot Project Award Program.
Patients undergoing a mastectomy often receive a pectoralis nerve block (PECS block), a pain management tool containing either bupivacaine or Exparel (liposomal bupivacaine) — both of which are approved by the Food and Drug Administration to be used for mastectomy pain management.
PECS blocks can either be administered by anesthesiologists before surgery under ultrasound guidance or by the surgeon after the mastectomy while the patient is still asleep. While both drugs and both ways to administer the PECS blocks are standards of care, no study has examined the optimal combination that is best at managing pain for patients.
The trial will enroll approximately 100 patients who will be randomized to either bupivacaine or Exparel, administered either before or during surgery. Patients will also be given non-opioid analgesic medications such as acetaminophen or ibuprofen before and after surgery to help manage their pain.
“The idea is how can we add different things to this so that we don’t need to use opioids exclusively, which is the way things were 10, 20 years ago in health care,” said Budde, a Cancer Center physician researcher and associate professor in the Department of Anesthesiology in UC’s College of Medicine. “If we can minimize the amount of opioids they use, patients will ultimately do better. I think this is a really cool approach to see if timing matters and if the medication used matters.”
“I do emphasize with patients that these are all standards of care and we’re still going to treat their pain. It doesn’t mean that if they’re enrolled in the study that we’re not going to give them pain medications,” said Heelan, a Cancer Center physician researcher, vice chair for quality and assistant professor in the Department of Surgery in UC’s College of Medicine. “We’re trying to take away some of the pain as much as we can when it’s already a tough process.”
Spectrum News and HemOnc Today also covered this research.
Watch or read the Spectrum News article.
Read the HemOnc Today article.
Featured photo at top of pink Breast Cancer Awareness ribbon. Photo/Lludmila Chernetska/iStock.
Stay connected with the Cancer Center
Interested in learning more about the University of Cincinnati Cancer Center? Keep up to date by signing up for communications and newsletters based on your specific interests. Sign up for Cancer Center communications.
Related Stories
Phase 1 trial tests probiotic treatment for radiation side effects in the gut
March 9, 2026
The University of Cincinnati Cancer Center’s Bailey Nelson, MD, has been awarded a $50,000 pilot grant from the Cancer Center to open a Phase 1 trial testing if a probiotic supplement can reduce gastrointestinal symptoms for patients undergoing whole pelvis radiotherapy.
Is uACR the key to cardiovascular and kidney disease prevention?
March 8, 2026
As a precision biomarker, the urinary albumin-to-creatinine ratio (uACR) can guide physicians toward personalized, patient-centered prevention and treatment of both cardiovascular disease (CVD) and chronic kidney disease (CKD), according to new data published in the Journal of Internal Medicine.
Driven by her own pain
March 8, 2026
Endometriosis is a painful and often debilitating disease that affects an estimated 6.5 million women in the U.S. It occurs when tissue similar to the lining of the uterus grows outside of it, causing pain, inflammation and sometimes infertility. Now a University of Cincinnati College of Medicine researcher is developing what is believed to be the first at-home diagnostic test.